EP123 – Clinical Behavior and Outcome of Papillary T1 Thyroid Cancers: Korea vs. Colombia vs. Turkey. A cohort study analyzing oncological outcomes

     

    Makay, Ozer1; Lee, Yong-Sang2; Dueñas, Juan Pablo3; Ozdemir, Murat1; Yazici, Bulent4; Akgun, Aysegul4; ?coz, Gokhan1; Akyildiz, Mahir1; Kim, Soo Young2; Kim, Bup Woo2; Kim, Seok-Mo2; Chang, Hojin2; Chang, Hang-Seok2; Park, Cheong Soo2
    Ege University Hospital, Dept. of General Surgery, Div. Endocrine Surgery, Izmir, Turkey
    Yonsei University, Gangnam Severance Hospital, Thyroid Cancer Center, Seoul, Korea
    Instituto de Cancerologia las Americas, Hospital Pablo Tobon Uribe, Medellin, Colombia
    Ege University Hospital, Dept. of Nuclear Medicine, Izmir, Turkey


    Background/Purpose:
    There has not been an international multicentric study to examine the relationship between thyroid cancer clinical outcomes and geographic location between Korea, Colombia and Turkey, whereas thyroid cancer is ranking in the first 3 in Korea and Turkey. The aim was to assess regional differences of T1 papillary thyroid cancer outcomes between countries.

    Methods: This is an observational non-randomized study. A total of 2720 patients who have been operated for T1 papillary thyroid cancer between 2011–2014 and are on routine follow-up have been recruited. All data was collected into a common-used database and analyses conducted using SPSS version 24. The mean follow-up was 46.4 ± 10.7 months.

    Results: Patients participated from Korea (88.2%), Turkey (9.1%) and Colombia (2.6%). Eighty percent were female. Female dominance tended to be higher in Colombia (p=0.01). Mean age at diagnosis was 45.2 years. There was no mortality. Recurrence tended to be higher in Colombia (p<0.001). Moreover, statistical analysis revealed differences among patients regarding symptoms (p<0.001), family history (p<0.001), euthyroidism (p<0.001), anti-Tg and/or anti-TPO positivity (p<0.001), FNAB results (p<0.001), type of resection (p<0.001), central node dissection (p<0.001), tumor size (p<0.001), multifocality (p<0.001), bilaterality (p<0.001), tumor subtype (p<0.001) and radioactive iodine treatment (p<0.01).

    Conclusion: Thyroid cancer is becoming more commonly diagnosed worldwide. This multinational study has identified differences in disease presentation, treatment approaches and outcome, which need to be investigated, especially by increasing the number of participating countries. Future comparisons will facilitate developments in treatment for the benefit of patient outcomes.

 

Leave a Reply

  • Upcoming Events

     

    World Congress on Thyroid Cancer 3.5
    Rome, Italy | 2019

    Steering Committee
    Rocco Bellatone, MD, Co-Chair
    Celestino Lombardi, MD, Co-Chair
    Gregory Randolph, MD
    Bryan McIver, MD
    Jeremy Freeman, MD
    Ian J. Witterick, MD
    Ashok R. Shaha, MD
    Jatin P. Shah, MD

    World Congress on Thyroid Cancer 4.0
    July 29 – August 1, 2021
    Boston, Massachusetts

     

  • WCTC3.5 Steering Committee:

     

    Rocco Bellatone, Co-Chair
    Celestino Lombardi, Co-Chair
    Gregory W. Randolph, MD
    Bryan McIver, MD
    Jeremy Freeman, MD
    Ian J. Witterick, MD
    Ashok R. Shaha, MD
    Jatin P. Shah, MD